Alnara Pharmaceuticals Secures $35 Million in Series B Round
Proceeds Will Further Advance Liprotamase Commercialization Efforts
CAMBRIDGE, Mass., January 28, 2010– Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors [...]
